Effects of the somatostatin receptor subtype 4 selective agonist J‐2156 on sensory neuropeptide release and inflammatory reactions in rodents
- 1 October 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (4) , 405-415
Abstract
Background and purpose: Substance P (SP) and calcitonin gene‐related peptide (CGRP) released from capsaicin‐sensitive sensory nerves induce local neurogenic inflammation; somatostatin exerts systemic anti‐inflammatory actions presumably via sst4/sst1 receptors. This study investigates the effects of a high affinity, sst4‐selective, synthetic agonist, J‐2156, on sensory neuropeptide release in vitro and inflammatory processes in vivo.Experimental approach: Electrically‐induced SP, CGRP and somatostatin release from isolated rat tracheae was measured with radioimmunoassay. Mustard oil‐induced neurogenic inflammation in rat hindpaw skin was determined by Evans blue leakage and in the mouse ear with micrometry. Dextran‐, carrageenan‐ or bradykinin‐induced non‐neurogenic inflammation was examined with plethysmometry or Evans blue, respectively. Adjuvant‐induced chronic arthritis was assessed by plethysmometry and histological scoring. Granulocyte accumulation was determined with myeloperoxidase assay and IL‐1β with ELISA.Key results: J‐2156 (10–2000 nM) diminished electrically‐evoked neuropeptide release in a concentration‐dependent manner. EC50 for the inhibition of substance P, CGRP and somatostatin release were 11.6 nM, 14.3 nM and 110.7 nM, respectively. J‐2156 (1–100 μg kg−1 i.p.) significantly, but not dose‐dependently, inhibited neurogenic and non‐neurogenic acute inflammatory processes and adjuvant‐induced chronic oedema and arthritic changes. Endotoxin‐evoked myeloperoxidase activity and IL‐1β production in the lung, but not IL‐1β‐ or zymosan‐induced leukocyte accumulation in the skin were significantly diminished by J‐2156.Conclusions and implications: J‐2156 acting on sst4 receptors inhibits neuropeptide release, vascular components of acute inflammatory processes, endotoxin‐induced granulocyte accumulation and IL‐1β synthesis in the lung and synovial and inflammatory cells in chronic arthritis. Therefore it might be a promising lead for the development of novel anti‐inflammatory drugs.British Journal of Pharmacology (2006) 149, 405–415. doi:10.1038/sj.bjp.0706876Keywords
This publication has 58 references indexed in Scilit:
- Inhibitory effect of somatostatin on inflammation and nociceptionPharmacology & Therapeutics, 2006
- TT-232Drugs of the Future, 2005
- The somatostatin analogue TT-232 induces apoptosis in A431 cells: Sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinasesCellular Signalling, 2001
- Identification and pharmacological characterization of somatostatin receptors in rat lungBritish Journal of Pharmacology, 1997
- Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal toleranceInflammation Research, 1995
- The somatostatin receptor familyLife Sciences, 1995
- Classification and nomenclature of somatostatin receptorsTrends in Pharmacological Sciences, 1995
- Somatostatin analogues suppress the inflammatory reaction in vivo.Journal of Clinical Investigation, 1994
- Antidromic vasodilatation and neurogenic inflammationInflammation Research, 1988
- Interleukin-3 modulation of mouse bone marrow derived mast cell receptors for somatostatinJournal of Neuroscience Research, 1987